Herold Johnny Metselaar

Herold Johnny Metselaar

Auto-generated profile, based on publicly available information

Herold Johnny Metselaar

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Journal of Hepatology
Verified
Journal Article
Open access
CVCornelia J. Verhoeven
Cornelia J. Verhoeven
WFWaqar R.R. Farid
Waqar R.R. Farid
JJJeroen de Jonge
Jeroen de Jonge
HMHerold J. Metselaar
Herold J. Metselaar
GKGeert Kazemier
Geert Kazemier
Luc J.W. van der LaanLuc J.W. van der Laan
Luc J.W. van der Laan
A global rising organ shortage necessitates the use of extended criteria donors (ECD) for liver transplantation (LT). However, poor preservation and extensive ischemic injury of ECD grafts have been recognized as important factors associated with primary non-function, early allograft dysfunction, and biliary complications after LT. In order to prevent for these ischemia-related complications, machine perfusion (MP) has gained interest as a technique to optimize preservation of grafts and to provide the opportunity to assess graft quality by screening for extensive ischemic injury. For this purpose, however, objective surrogate biomarkers are required which can be easily determined at time of graft preservation and the various techniques of MP. This review provides an overview and evaluation of biomarkers that have been investigated for the assessment of graft quality and viability testing during different types of MP. Moreover, studies regarding conventional graft preservation by static cold storage (SCS) were screened to identify biomarkers that correlated with either allograft dysfunction or biliary complications after LT and which could potentially be applied as predictive markers during MP. The pros and cons of the different biomaterials that are available for biomarker research during graft preservation are discussed, accompanied with suggestions for future research. Though many studies are currently still in the experimental setting or of low evidence level due to small cohort sizes, the biomarkers presented in this review provide a useful handle to monitor recovery of ECD grafts during clinical MP in the near future.

15 April 2009 in Transplantation
Verified
Journal Article
Closed access
ADAhmet Demirkiran
Ahmet Demirkiran
VSVarsha D. K. D. Sewgobind
Varsha D. K. D. Sewgobind
JWJoyce van der Weijde
Joyce van der Weijde
AKAlice Kok
Alice Kok
Carla C. BaanCarla C. Baan
Carla C. Baan
Luc J.W. van der LaanLuc J.W. van der Laan
Luc J.W. van der Laan
Background. CD4+Foxp3+ regulatory T cells (Treg) depend on interleukin (IL)-2 for their function and survival. By interfering with the IL-2 production, calcineurin inhibitors (CNI) may negatively affect Treg. Here, we describe the effects of conversion from CNI to mycophenolate mofetil (MMF) monotherapy on renal function, and on Treg frequency and phenotype in liver transplant recipients. Methods. Patients (n=16) with renal impairment on CNI were converted to MMF and received a single dose of IL-2-receptor blocking antibody (Daclizumab). Control patients (n=8) continued CNI treatment. Results. Renal function rapidly and significantly improved after conversion. Daclizumab treatment resulted in a 75% blocking of CD25 at 1 month causing a significant reduction in the percentage of CD4+CD25+ cells but not affecting the percentage of CD4+CD25+Foxp3+ cells. Six months after conversion to MMF, the percentage of CD4+CD25+Foxp3+ cells increased significantly by 125%. FOXP3 mRNA analysis of mononuclear cells confirmed the enrichment of Foxp3 in peripheral blood. Interestingly, the CD25 expression level on CD4+Foxp3+, but not CD4+Foxp3−, cells significantly increased compared with preconversion. Conclusion. Conversion to MMF increases the percentage and CD25 expression of CD4+Foxp3+ cells indicating that MMF therapy can overturn the repressive effect of CNI on circulating Treg levels and therefore may promote Treg-mediated suppression of alloreactivity.

25 June 2010 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
ATAngela S. W. Tjon
Angela S. W. Tjon
JNJerome Sint Nicolaas
Jerome Sint Nicolaas
JKJaap Kwekkeboom
Jaap Kwekkeboom
RMRobert A. de Man
Robert A. de Man
GKGeert Kazemier
Geert Kazemier
HMHerold J. Metselaar
Herold J. Metselaar
The goal of this study was to determine the risk factors for de novo cancer after liver transplantation (LTx). Retrospective analyses were performed in 385 LTx patients who underwent transplantation between 1986 and 2007. In total, 50 (13.0%) recipients developed de novo malignancy. The cumulative incidence of de novo cancer at 1, 5, 10, and 15 years after LTx was 2.9% ± 0.9%, 10.5% ± 1.8%, 19.4% ± 3.0%, and 33.6% ± 6.8%, respectively. The standardized incidence ratio of malignancy in LTx patients compared to the general population was 2.2 (95% confidence interval: 1.6-2.8). After excluding posttransplant lymphoproliferative disorder and skin cancer, patients with de novo cancer had a significantly lower survival rate compared to recipients who remained cancer-free. The identified univariate risk factors for de novo cancer were cyclosporine A (CsA) treatment, time period of LTx, and recipient age. In multivariate analysis, only CsA treatment emerged as an independent risk factor for de novo cancer, which was attributed to more aggressive cancer types. A surprising finding was that CsA treatment specifically enhanced cancer risk in patients who underwent transplantation after 2004, when C2 monitoring (blood concentration at 2 hours postdose) was introduced. In addition, these patients showed a significantly lower acute rejection rate, which might reflect a more robust immunosuppressive status caused by the CsA-C2 regimen. When age was considered, only patients ≤50 years had a higher cancer rate when treated with CsA compared to treatment with tacrolimus. Our data suggest that, compared to tacrolimus treatment, CsA treatment with C2 monitoring or in younger patients of ≤50 years is associated with a higher early de novo cancer risk after LTx. Liver Transpl 16:837–846, 2010. © 2010 AASLD.

4 September 2017 in Transplant International
Verified
Journal Article
Closed access
PDF file
JVJeroen L. A. Van Vugt
Jeroen L. A. Van Vugt
SBStefan Büttner
Stefan Büttner
LALouise J. M. Alferink
Louise J. M. Alferink
NBNiek Bossche
Niek Bossche
RBRon W. F. de Bruin
Ron W. F. de Bruin
JIJan N. M. Ijzermans
Jan N. M. Ijzermans
Low skeletal muscle mass (sarcopenia) is associated with increased morbidity and mortality in liver transplant candidates. We investigated the association between sarcopenia and hospital costs in patients listed for liver transplantation. Consecutive patients with cirrhosis listed for liver transplantation between 2007 and 2014 in a Eurotransplant centre were identified. The skeletal muscle index (SMI, cm2/m2) was measured on CT performed within 90 days from waiting list placement. The lowest sex‐spe cific quartile represented patients with sarcopenia. In total, 224 patients were included. Median time on the waiting list was 170 (IQR 47–306) days, and median MELD score was 16 (IQR 11–20). The median total hospital costs in patients with sarcopenia were €11 294 (IQR 3570–46 469) compared with €6878 (IQR 1305–20 683) in patients without sarcopenia (P = 0.008). In multivariable regression analysis, an incremental increase in SMI was significantly associated with a decrease in total costs (€455 per incremental SMI, 95% CI 11–900, P = 0.045), independent of the total time on the waiting list. In conclusion, sarcopenia is independently associated with increased health‐related costs for patients on the waiting list for liver transplantation. Optimizing skeletal muscle mass may therefore lead to a decrease in hospital expenditure, in addition to greater health benefit for the transplant candidate.

27 May 2020 in Transplant International
Verified
Journal Article
Closed access
PDF file
RHRogier A. S. Hoek
Rogier A. S. Hoek
OMOlivier C. Manintveld
Olivier C. Manintveld
MBMichiel GH Betjes
Michiel GH Betjes
MHMerel Hellemons
Merel Hellemons
LSLeonard Seghers
Leonard Seghers
TGthe Rotterdam Transplant Group
the Rotterdam Transplant Group
Background Solid organ transplant (SOT) recipients may be at risk for severe COVID‐19. Data on the clinical course of COVID‐19 in immunosuppressed patients are limited and the effective treatment strategy for these patients is unknown. Methods We describe our institutional experience with COVID‐19 in SOT. Demographic, clinical and treatment data were extracted from the electronic patient files. Results A total of 23 SOT transplant recipients suffering from COVID‐19 were identified (n = 3 heart; n =15 kidney; n = 1 kidney‐after‐heart; n = 3 lung and n = 1 liver transplant recipient). The presenting symptoms were similar to non‐immunocompromised patients Eighty‐three percent (19/23) of the patients required hospitalization but only two of these were transferred to the intensive care unit. Five patients died from COVID‐19; all had high Clinical Frailty scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only 3 patients were treated with chloroquine. Most patients recovered without experimental anti‐viral therapy. Conclusions Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID‐19. Pre‐existent frailty is associated with death from COVID‐19.

24 May 2021 in Transplant International
Verified
Journal Article
Open access
PDF file
TVThijmen Visseren
Thijmen Visseren
NENicole Stephanie Erler
Nicole Stephanie Erler
Wojciech G. Transplant PolakWojciech G. Transplant Polak
Wojciech G. Transplant Polak
RARené Adam
René Adam
VKVincent Karam
Vincent Karam
T(The European Liver and Intestine Transplantation Association (ELITA)
The European Liver and Intestine Transplantation Association (ELITA)
Background Liver transplantation for primary sclerosing cholangitis (PSC) can be complicated by recurrence of PSC (rPSC). This may compromise graft survival but the effect on patient survival is less clear. We investigated the effect of post-transplant rPSC on graft and patient survival in a large European cohort. Methods Registry data from the European Liver Transplant Registry regarding all first transplants for PSC between 1980 and 2015 were supplemented with detailed data on rPSC from 48 out of 138 contributing transplant centres, involving 1,549 patients. Bayesian proportional hazards models were used to investigate the impact of rPSC and other covariates on patient and graft survival. Results Recurrence of PSC was diagnosed in 259 patients (16.7%) after a median follow-up of 5.0 years (quantile 2.5%-97.5%: 0.4–18.5), with a significant negative impact on both graft (HR 6.7; 95% CI 4.9–9.1) and patient survival (HR 2.3; 95% CI 1.5–3.3). Patients with rPSC underwent significantly more re-transplants than those without rPSC (OR 3.6, 95% CI 2.7–4.8). Conclusions PSC recurrence has a negative impact on both graft and patient survival, independent of transplant-related covariates. Recurrence of PSC leads to higher number of re-transplantations and a 33% decrease in 10-year graft survival.